Ali Tehrani, Zymeworks CEO
Zymeworks squares up with Herceptin after HER2 bispecific aces mid-stage test in esophageal cancer
Roche’s Herceptin has long stood as standard of care across multiple advanced cancers, but a suite of next-gen players are looking to beat the aging …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.